Massive trial tests antibiotic jab to stop blinding infection after cataract surgery
NCT ID NCT03244072
First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 2 times
Summary
This study will test whether a single antibiotic injection given during cataract surgery can prevent endophthalmitis, a rare but severe eye infection. About 60,000 people with cataracts will receive either the antibiotic or a placebo. The goal is to see if the antibiotic reduces the number of infections after surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- moxifloxacin (antibiotic eye injection)
- What this could lead to
- If it works, this could become a standard way to prevent a rare but serious eye infection after cataract surgery.
- What could go wrong
- This is a large but still early-phase trial. The infection is already rare, so proving a benefit is challenging, and there is a small risk of allergic reaction or injection-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 60,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2027
An estimate. Start dates often move.
- Expected to finish
-
Oct 2031
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * visually significant cataracts Exclusion Criteria: * allergy to fluoroquinolones, cobalamin (B12)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cataract are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Zion Eye Institute
St. George, Utah, 84790, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A lens that could let cataract patients see near and far without glasses
- One operation for cataract and glaucoma? eye surgeons test a Two-in-One approach
- Eye drops may shield the cornea after cataract surgery
- A simple blood draw might reveal hidden eye lymphoma
- Can a new lens make glasses obsolete after cataract surgery?
- Can a new lens design sharpen vision after macular surgery?